175 related articles for article (PubMed ID: 11535501)
1. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles FJ; Faderl S; Kantarjian HM
Blood; 2001 Sep; 98(6):1708-13. PubMed ID: 11535501
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
3. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
4. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
7. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.
Lipton JH; Khoroshko N; Golenkov A; Abdulkadyrov K; Nair K; Raghunadharao D; Brummendorf T; Yoo K; Bergstrom B;
Leuk Lymphoma; 2007 Mar; 48(3):497-505. PubMed ID: 17454589
[TBL] [Abstract][Full Text] [Related]
8. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
9. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.
Bukowski RM; Tendler C; Cutler D; Rose E; Laughlin MM; Statkevich P
Cancer; 2002 Jul; 95(2):389-96. PubMed ID: 12124839
[TBL] [Abstract][Full Text] [Related]
10. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Jabbour E; Kantarjian H; Cortes J; Thomas D; Garcia-Manero G; Ferrajoli A; Faderl S; Richie MA; Beran M; Giles F; Verstovsek S
Cancer; 2007 Nov; 110(9):2012-8. PubMed ID: 17849460
[TBL] [Abstract][Full Text] [Related]
11. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD
J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213
[TBL] [Abstract][Full Text] [Related]
12. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation.
Higano CS; Raskind WH; Singer JW
Blood; 1992 Sep; 80(6):1437-42. PubMed ID: 1520870
[TBL] [Abstract][Full Text] [Related]
13. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
[TBL] [Abstract][Full Text] [Related]
14. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.
Michallet M; Maloisel F; Delain M; Hellmann A; Rosas A; Silver RT; Tendler C;
Leukemia; 2004 Feb; 18(2):309-15. PubMed ID: 14671645
[TBL] [Abstract][Full Text] [Related]
15. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
Cortes J; Quintás-Cardama A; Jones D; Ravandi F; Garcia-Manero G; Verstovsek S; Koller C; Hiteshew J; Shan J; O'Brien S; Kantarjian H
Cancer; 2011 Feb; 117(3):572-80. PubMed ID: 20886606
[TBL] [Abstract][Full Text] [Related]
16. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
[TBL] [Abstract][Full Text] [Related]
17. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Nicolini FE; Hayette S; Legros L; Rousselot P; Maloisel F; Tulliez M; Guerci A; Charbonnier A; Prébet T; Rigal-Huguet F; Chabane K; Magaud JP; Paillet C; Pivot C; Michallet M
Leuk Res; 2011 Jan; 35(1):80-6. PubMed ID: 20605207
[TBL] [Abstract][Full Text] [Related]
18. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
[TBL] [Abstract][Full Text] [Related]
19. Interferon alpha-2b as therapy for patients with Ph'-positive chronic myelogenous leukemia.
Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
Eur J Haematol Suppl; 1990; 52():25-8. PubMed ID: 2279541
[TBL] [Abstract][Full Text] [Related]
20. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]